CBD and THC Interaction Evidence Does Not Cover All Patient Populations Equally
A 2024 review found CBD and THC pharmacokinetics and drug interactions poorly characterized in several special populations. Evidence from a healthy-volunteer or disease-specific trial does not establish the same interaction magnitude in every patient group.
The populations were heterogeneous
The review discussed pregnancy and lactation, childhood, older age and hepatic or renal impairment, among other settings. These groups cannot be assigned one common exposure pattern merely because they differ from a typical healthy-volunteer sample. The physiological assumptions behind a prediction matter.
Known mechanisms do not settle every co-medication question
Some therapeutic drug interactions have been studied, particularly involving antiepileptic treatment, while many remain unexamined. A plausible enzyme-related mechanism does not itself establish the interaction magnitude, clinical consequence or required dose change for an untested medicine.
Population coverage is a separate evidence requirement
A conclusion from one age group or physiological setting cannot fill every gap in another. The review called for interaction studies involving medicines commonly used within these populations. This is a question of direct evidence coverage: absence of a relevant study does not establish either the presence or absence of a clinically important interaction.
Interpreting the evidence
A sound interaction claim identifies the cannabinoid preparation, co-medication, population and evidence type. This review supports targeted research rather than a universal interaction table. It does not provide individualized prescribing or medication-adjustment instructions.
Related reading: interpreting cannabis tolerance claims.
Research reference
Lixuan Qian; Jessica L. Beers; Klarissa D. Jackson; Zhu Zhou (2024). CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions. Pharmaceutics. doi:10.3390/pharmaceutics16040484.
This discussion draws on the abstract and introductory material in the supplied research synthesis.
